How many investments has Sofinnova Ventures made?

Sofinnova Ventures has 219 tracked investments, 52 of which have exited, including 15 dated in the last 24 months.

What stage does Sofinnova Ventures invest at?

Sofinnova Ventures invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Sofinnova Ventures's typical check size?

Sofinnova Ventures typically writes checks of $100K – $15M.

What sectors does Sofinnova Ventures focus on?

Sofinnova Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Sofinnova Ventures located?

Sofinnova Ventures is headquartered in Menlo Park, US.

Does Sofinnova Ventures lead rounds?

Sofinnova Ventures typically participates in rounds rather than leading them.

Who does Sofinnova Ventures co-invest with?

Sofinnova Ventures most often shares deals with RA Capital, Foresite Capital, New Enterprise Associates (NEA), among 150 tracked co-investors.

Sofinnova Ventures

Venture capitalActively deploying

Menlo Park · Seed–Late Stage · 49 people tracked

Also known as Sofinnova Investments, Inc. · Sofinnova Venture Partners

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Sofinnova Ventures

Each arrow is one introduction. Sign up to fill in the first one.

366 people can intro you to Jakob

Ask Bill Grossman to introduce you to Jakob Dupont

You →Bill · together at Bolt Biotherapeutics →Jakob

311 people can intro you to Jonathan

Ask Jamie Chen to introduce you to Jonathan Leff

You →Jamie · together at Northsea Therapeutics →Jonathan

218 people can intro you to Chris

Ask Sam Okafor to introduce you to Chris Carpenter

You →Sam · together at Catamaran Bio →Chris

Maha Katabi212 people can intro you
Nathalie Auber114 people can intro you
Lars Ekman102 people can intro you

Your email: who you already know at Sofinnova Ventures, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sofinnova Ventures team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

Sofinnova concentrates on backing transformative biotech companies across their full lifecycle. The firm positions itself as a hands-on, experienced partner that supports founders from a company's inception through the stages of drug development, navigating the regulatory process, building the organization, and reaching a public offering. Its emphasis is on life sciences innovation, working collaboratively with entrepreneurs through every phase of growth.

Invests inBiotech Digital Health Healthtech Medical Devices Global Menlo Park North America United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Late Stage

Check

$100K – $15M

Menlo Park, CA, US

Leads rounds

Follows

Instruments

Equity

Founded

1976

Last 12 months

10 investments

AUM

$5.4B

Tracked investments

219

Unicorns

IPOs

Acquisitions

Team · 49 people

from the firm's website & curated & public directories

Aneal Tenjarla· Partner, Associate Portfolio Manager, Public Equity· Menlo Park, California, United Statesin

Aneal Tenjarla is a Partner and Associate Portfolio Manager for Sofinnova BioEquities, concentrating on public investments in global biotechnology, pharmaceutical, and medical technology companies, with more than ten years in public healthcare investing. Before joining Sofinnova in 2019, he spent five years as a Senior Analyst at Citadel managing a healthcare-focused portfolio, and earlier worked as an Analyst at Point72 covering healthcare and as an investment banker at Greenhill focused on healthcare M&A. He holds an M.S. in Biotechnology from Johns Hopkins and a B.B.A. from the University of Texas at Austin.

Chris Carpenter· Partner· Cambridge, Massachusetts, United Statesin

Chris Carpenter is an oncology physician-scientist with over two decades of clinical and laboratory experience who joined Sofinnova in 2022, focusing on clinical-stage product companies in oncology, rare diseases, and specialty therapeutics. He previously served as Chief Medical Officer at CatamaranBio and Rubius Therapeutics, and led cancer epigenetics at GlaxoSmithKline as well as drug development work at Merck. He holds a B.S. from Stanford University and M.D. and Ph.D. degrees from the University of Southern California, and is board certified in internal medicine and medical oncology.

chris@sofinnova.com

Eric Delbridge· General Partner, Public Equity

Eric Delbridge is a General Partner at Sofinnova Ventures, where he leads development of the firm's BioEquities strategy focused on public investments in global therapeutics companies. He joined Sofinnova in 2016 after managing market neutral therapeutics and healthcare portfolios at Balyasny Asset Management, and was previously a Partner at Spring Point Capital (formerly Botti Brown Asset Management) and a healthcare investment banker at Lazard and Credit Suisse. He holds an M.D. from Northwestern University, an M.B.A. from The Wharton School, and a B.A. in Classics from Yale University.

Hooman Shahlavi· Partner & Chief Legal Officer· Menlo Park, California, United Statesin

Hooman Shahlavi handles legal matters at Sofinnova, including the structuring, negotiation, and execution of initial and follow-on investments, restructurings, major corporate transactions, exits, and wind-downs, as well as compliance, fund formation, and risk and director liability issues. He joined the firm in 2007 after practicing as an attorney at O'Melveny & Myers (2003-2007) and Brobeck, Phleger & Harrison, where he worked on venture capital, M&A, and public offering transactions. He holds a J.D. from the University of California, Hastings College of Law and a B.S. in Business Administration from San Jose State University.

Jakob Dupont· Partner· Boston, Massachusetts, United Statesin

Jakob Dupont is a physician with over two decades of experience in oncology and other therapeutic areas, focused on developing therapies for high unmet medical needs. Before joining Sofinnova in 2023, he held senior R&D and medical leadership roles at Atara Biotherapeutics, Gossamer Bio, Genentech/Roche, and OncoMed Pharmaceuticals. He earned his M.D. from Cornell University's Weill Medical College and an M.A. in philosophy from New York University, and completed his oncology fellowship at Memorial Sloan Kettering Cancer Center.

jakob@sofinnova.com

Jim Healy· Managing Partner· Menlo Park, California

Jim Healy has spent about twenty years investing at Sofinnova, backing thirty-two companies in the biotechnology and healthcare space, many of which have gone public or been acquired. He holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from UC Berkeley, and earned his MD and PhD in Immunology from Stanford University through the NIH Medical Scientist Training Program. Before Sofinnova, he worked at Bayer (Miles) and Sanderling, and has lectured on entrepreneurship at Stanford.

jim@sofinnova.com

Jonathan Leff· Executive Partner, Private Equity· Menlo Park, Californiain

Jonathan Leff is a physician with over 25 years of clinical development experience in the biotechnology and pharmaceutical industry, advising companies on drug development from target identification through market approval. Before joining Sofinnova in 2020, he was SVP and Chief Medical Officer of Ascendis Pharma, EVP of Research and Development at InterMune (where he led development and US approval of Esbriet for idiopathic pulmonary fibrosis), and held CMO roles at KaloBios Pharmaceuticals and Halozyme Therapeutics, plus positions at Roche, Amgen, and Merck. He holds a B.A. in Chemistry and an M.D. from the University of Pennsylvania, and completed training in Internal Medicine and Pulmonary and Critical Care Medicine at the University of Colorado, Denver.

jonathan@sofinnova.com

Lars Ekman· Partner· San Diego, Californiain

Lars Ekman is a global R&D executive and drug developer with more than 30 years of experience across executive, scientific, and clinical roles, and he brings his life science background to the investment team. Before joining Sofinnova in 2008, he was President of Research and Development at Elan, having earlier held R&D leadership at Schwarz Pharma AG and various senior scientific and clinical roles at Pharmacia (now Pfizer). He earned his MD and PhD from the University of Gothenburg, Sweden, and is a board-certified surgeon with a PhD in Experimental Biology.

ekman@sofinnova.com

Maha Katabi· General Partner· Montrealin

Maha Katabi is a PhD in Pharmacology and CFA who built crossover public/private biotech investing platforms, focuses on clinical‑stage single‑asset radiopharmaceutical and targeted oncology companies, and chairs Exactis Innovation.

maha@sofinnova.com

Maha Radhakrishnan· Partner

Maha Radhakrishnan is an industry executive with decades of experience in product development, commercialization, and global medical strategy across biotechnology and pharmaceutical companies. Before joining Sofinnova in 2024, she served as Consultant to the CEO at Dyne Therapeutics, Chief Medical Officer at Biogen, and Senior Vice President and Global Head of Medical for the Primary Care Business Unit at Sanofi, with earlier leadership roles at Bioverativ, Bristol Myers Squibb, United Health Group, and Cephalon. She holds an M.D. in internal medicine from the People's Friendship University in Moscow and a master's degree in Russian language.

Nathalie Auber· Partner & CFO· San Francisco Bay Areain

Nathalie Auber has more than twenty years of private equity experience across financial reporting, operations, and deal structuring, and works with the investment team on financings, exit strategy, and valuations. She leads Sofinnova's Finance & Accounting team and administrative functions, having joined the firm in 1996. Earlier in her career she served as Director of Internal Audit at Catellus Development and spent seven years as an auditor with Deloitte and Touche in Paris and San Francisco.

auber@sofinnova.com

Daniel Ni, MD, PhD· Analyst, Public Equity

Justin Lee, PhD· Analyst, Private Equity

Merdad Parsey, MD, PhD· Executive Partner, Private Equity

Ricardo Grieshaber-Bouyer, MD, PhD, MHBA· Venture Partner, Private Equity

Alex Chan· Controller, Private Equity

Alex Chan joined Sofinnova's Finance Department in 2013 as Senior Accountant and became Controller in 2021, handling the day-to-day accounting for the firm and its funds. Before Sofinnova, he worked at an international public accounting firm providing assurance and advisory services to public and private companies in the IT and biotech sectors. He holds a B.A. in Economics from UCLA and is a Certified Public Accountant in California.

Alex Dulnev· IT Manager· Menlo Park, California, United Statesin

Amanda Phillips· Executive Assistant· Menlo Park, California, United Statesin

Amanda Phillips is an Executive Assistant at Sofinnova Investments, with experience in the venture capital and private equity industry. Her areas of work include event planning, office administration, calendaring, onboarding, and human resources. She holds a Bachelor of Arts in Human Development from California State University-Hayward.

Anastasia Voevodin· Analyst, Public Equity

Anastasia Voevodin joined Sofinnova BioEquities as an Analyst in 2024, where she focuses on public biotech investments. She previously worked as a Senior Research Associate at Avoro Capital covering public biotech, and as a management consultant at ZS Associates serving biotech clients. She holds a PhD in Chemistry from Columbia University and a BA in Chemistry with a Biomedical Engineering Science minor from Boston University.

Calvin Sternick· Analyst, Public Equity

Calvin Sternick joined Sofinnova BioEquities as an Analyst in 2026, working on public investments in healthcare services. He previously worked as an Analyst at Millennium Management covering areas such as contract research organizations, hospitals, laboratories, and managed care organizations, and served as Vice President of Managed Care & Facilities Equity Research at JPMorgan Chase. Earlier roles included healthcare equity research at TD Cowen and FBR Capital Markets and a structured finance valuation position at EY; he holds a B.S. in Accounting from Binghamton University.

David Kabakoff· Executive Advisor, Private Equity

David Kabakoff is a medicinal chemist with more than 30 years of experience leading technology and product development in the pharmaceutical, biopharmaceutical, and drug delivery fields. Before joining Sofinnova in 2007, he co-founded the cancer drug developer Salmedix, serving as Chairman and CEO until its acquisition by Cephalon, and previously held executive roles at Dura, Spiros Development, Corvas International, and Hybritech. He holds a PhD from Yale University and a BA from Case Western Reserve University.

david@sofinnova.com

Debbie Murray· Chief People Officer· Menlo Park, California, United Statesin

Debbie Murray joined Sofinnova as Chief People Officer in 2020, where she leads strategic and operational initiatives tied to business performance goals. She previously served as Chief People Officer at BlueJeans Network and as Vice President at DataStax, Inc., where she oversaw human resources and business administration during the company's early growth. She holds a B.A. in Speech Communication from the University of San Diego.

Dina Hauser· Executive Assistant· Menlo Park, California, United Statesin

Eric Hsu· Analyst, Private Equity· Boston, Massachusetts, United States

Eric Hsu joined Sofinnova as an Analyst in 2025, focusing on biopharmaceutical company investments across multiple disease areas and therapeutic modalities. He earned a PhD in Neuroscience from Johns Hopkins University, where his research in Dr. Dwight Bergles' lab used microscopy methods to study non-neuronal cell signaling in the brain and the effects of ketamine on that signaling. He previously held a BA in Neuroscience from Washington University in St. Louis and served as a Venture Fellow for Insight Partners and Sofinnova.

Gina Baker· Compliance & Operations Manager, Public Equity

Gina Baker joined Sofinnova in 2022 as a Compliance/Operations Manager, handling operations for Sofinnova BioEquities and helping oversee firm compliance. She previously served as Senior Finance Manager of the public equities division at Vista Equity Partners and has held compliance, finance, and operations roles at investment firms including SPO Partners and Apex Capital. She holds a B.S. in Business Administration with emphases in Accounting and Corporate Management from California State University, Hayward.

James Brody· Chief Compliance Officer & Chief Operating Officer, Public Equity

Jim Brody joined Sofinnova in 2016 as Chief Compliance Officer for the firm and Chief Operating Officer for Sofinnova BioEquities. He previously served as Chief Compliance Officer and Managing Director of Operations at Apex Capital, LLC, and held earlier roles at Pershing, Nollenberger Capital Partners, Wells Fargo Securities, and Robertson Stephens. He holds an M.B.A. from the University of San Francisco and a B.S. from the University of Oregon.

Jenn Symmons· Events Manager & Executive Assistant· Menlo Park, California, United Statesin

John Barrett· Senior Analyst, Public Equity· Boston, Massachusetts, United Statesin

John Barrett is a Senior Analyst at Sofinnova BioEquities, where he works on public biotech investments across all therapeutic areas. He previously worked as a biotech analyst at Parkman Healthcare Partners covering SMid cap therapeutic areas and at Leerink covering SMid cap oncology. He holds a Ph.D. in Molecular Engineering from the University of Chicago and a B.S. in Biomedical Engineering from Boston University.

Josie Kastelic· Menlo Park Office Manager & Executive Assistant· Menlo Park

Kasey Olson· Boston Office Manager & Executive Assistant· Boston

Kathy Du· Vice President of Finance, Public Equity

Kathy Du joined Sofinnova in 2025 as Vice President of Finance for the Public Equity team, overseeing the financial operations of Sofinnova Public Markets. She previously served as Chief Financial Officer at One01 Capital and held controller roles at Paradigm and Passport Capital. She earned a B.S. in Business Administration with an accounting emphasis from the University of California, Berkeley, and is an inactive Certified Public Accountant.

Katrin Viller· Vice President Finance, Private Equity

Katrin Viller joined Sofinnova as Vice President of Finance in 2024, where she oversees the financial aspects of Sofinnova Venture funds. She previously served as Head of Finance at Kleiner Perkins and held several roles at PricewaterhouseCoopers in Estonia and San Jose, including auditing asset management and life science clients. She holds a B.A. in International Business from Estonian Business School and is a Certified Public Accountant in California.

Laurel Russell· New York Office Manager & Executive Assistant· New Yorkin

Lesley Weber· Executive Assistant

Mike Van· Associate, Private Equity· Stanford, California, United Statesin

Mike Van joined Sofinnova as an Analyst in 2022 and became an Associate in 2024, where he focuses on biopharmaceutical companies and investments. He earned a PhD in Biology from Stanford University, working in Lacramiora Bintu's lab on CRISPR-based epigenome editing tools, and holds a BS in Biochemistry and Molecular Biology from UC Davis. During his time at Stanford he was a venture fellow at Sofinnova and consulted in roles at biotech companies including Maze Therapeutics, Octant, and Wearlinq.

van@sofinnova.com

Naomi Pacalin· Associate, Private Equity· San Francisco Bay Area

Naomi Pacalin joined Sofinnova as an Analyst and became an Associate in 2025, where she works on biopharmaceutical company investments across multiple disease areas and therapeutic modalities. She holds a PhD in Bioengineering from Stanford University, where her research in Howard Chang's lab covered epigenomics and gene regulation using CRISPR epigenetic editing and single-cell sequencing. She also earned a BS in Biological Chemistry and a BA in Chemistry from the University of Chicago, and previously served as a Sofinnova Venture Fellow.

naomi@sofinnova.com

Nick Lenard· Analyst, Public Equity

Nick Lenard joined Sofinnova BioEquities as an Analyst in 2025, where he works on public investments in biotechnology and pharmaceutical companies globally. He previously spent over four years on the sell side covering SMid and Large Cap Biotechnology, most recently as a Vice President at J.P. Morgan. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Chemistry from Kenyon College.

Paul Chang· Analyst, Public Equity· Greater Chicago Areain

Paul Chang is an Analyst who joined Sofinnova BioEquities in 2025, where he works on public investments in medical technology and diagnostics. He previously served as an Investment Associate at TPG Growth, sourcing healthcare investments and supporting portfolio companies, and before that was an investment banker at Goldman Sachs covering healthcare M&A and financing. He holds a BS in Finance with a minor in English Literature from New York University.

Perry Nisen· Executive Advisor, Private Equity· San Diego, Californiain

Perry Nisen is a physician scientist with experience in drug discovery and development, focusing on pre-clinical and clinical companies in oncology, neuroscience, and immunology/inflammation. He joined Sofinnova in 2018 and previously served as CEO of the Sanford Burnham Prebys Medical Discovery Institute and held senior roles at GlaxoSmithKline, including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head, as well as a cancer research leadership role at Abbott Laboratories. He earned a BS from Stanford University and an MD/PhD from the Albert Einstein College of Medicine.

perry@sofinnova.com

Rachel Urrutia· Finance and HR Coordinator· Chicago, Illinois, United Statesin

Rachel Urrutia is a Finance & HR Coordinator at Sofinnova Investments. She has experience as a Finance & HR Coordinator and Executive Assistant across the venture capital, private equity, and biotechnology sectors.

Raymond Bower· Portfolio Manager, Synergy Fund· Seattle, Washington, United Statesin

Ray Bower joined Sofinnova in 2022 as Portfolio Manager of the Synergy Fund, concentrating on biotechnology and therapeutics. His earlier career included work as a medical director of a primary care clinic and in biologic product strategy at Centocor, followed by sell-side work at Citigroup, a partner and analyst role covering healthcare at Lee Munder Capital Group in Boston, running a biotech portfolio at TIAA CREF, and serving as Principal at Adenium Research. He holds a Bachelor of Medical Science and an M.D. from the University of Alberta and an MBA from the Wharton School at the University of Pennsylvania.

Seth Filbrun· Associate, Public Equity· New York City Metropolitan Areain

Seth Filbrun joined Sofinnova as an Associate in 2026 with Sofinnova BioEquities, where he works on public biotech investments. He previously worked as an Equity Research Associate at Stifel Financial covering small- and mid-cap biotech companies in immunology & inflammation and endocrinology, and before that as a Senior Consultant at Simon Kucher. He holds a Ph.D. in Analytical Chemistry from Georgia State University, an M.S. in Chemistry from Illinois State University, and a B.S. in Chemistry from Miami University.

Smita Chowdhri· Controller, Public Equity· Menlo Park, California, United Statesin

Smita Chowdhri joined Sofinnova BioEquities as a Controller in 2026, handling accounting and finance for the public equity team. She previously served as Controller at Intrinsic Edge Capital Management and held roles at Gen II Fund Services, Jump Trading, Jump Capital, Wolverine Asset Management, and Navigant Consulting, where her work spanned fund accounting, investor reporting, regulatory compliance, and forensic accounting. She holds a Bachelor of Science in Finance, Accounting, and Business Process Management from Indiana University and is a CPA in Illinois.

Steve Bilawey· IR and Marketing, Public Equity

Surin Kim· Financial Analyst, Private Equity· San Francisco, California

Surin Kim joined Sofinnova in 2021 as a Financial Analyst, handling fund accounting and tax matters. He previously worked as a Tax Senior at BDO USA, LLP, focusing on tax issues related to alternative investments, and earlier served as a private banker at Mirae Asset Securities (Daewoo Securities) in South Korea. He holds a Master of Science in Taxation from Golden Gate University and a Bachelor's degree in Business Administration from Inha University.

Tiffany Davis· Director of IR and Marketing, Private Equity

Troy Ignelski· Executive Advisor, Private Equity

Troy Ignelzi· Executive Advisor, Private Equity

Jonathan Leff· Partner· New York, New York

Founder mafia

3 people who came through Sofinnova Ventures went on to found or lead other companies.

Greg MondrePartner and CFOFounded Silver Lake Perry NisenExecutive Advisor, Private EquityFounded Quanta Therapeutics Srini AkkarajuGeneral PartnerFounded Tentarix

What they invest in

from 128 of 219 portfolio companies

Biotech ×117Healthtech ×56Medical Devices ×44Deep Tech ×12Digital Health ×12AI & Machine Learning ×7Data & Infrastructure ×3Hardware ×3

HQs:United States×101Denmark×2France×2United Kingdom×2Israel×2Netherlands×2

Who they back

founder profiles across 51 portfolio companies

55%

solo founders

28 of 51 mapped founding teams

31%

repeat founders

of 42 founders with career history

~4 yrs

old at investment

median across 26 dated deals

Founding team size:solo founder×282 founders×163 founders×34+ founders×4

Where their founders studiedfrom 35 founders with education data

Harvard University ×3KU Leuven ×3Massachusetts Institute of Technology ×3Harvard Medical School ×2Tulane University ×2Université Louis Pasteur (Strasbourg I) ×2University of California, Berkeley ×2University of Michigan ×2

What their founders studiedfrom 34 founders with field-of-study data

Life Sciences ×17Medicine ×9Chemistry ×6Engineering ×5Business & Management ×3Computer Science ×3Economics ×2Finance & Accounting ×2

Where their founders worked beforefrom 42 founders with career history

Galapagos ×9Aligos Therapeutics ×3Harvard Medical School ×3Johnson & Johnson ×3Broad Institute of MIT and Harvard ×2Flexus Biosciences ×2Janssen Europe, Middle East & Africa (EMEA) ×2

19 founders hold a PhD · 2 hold an MBA (of 37 with degree data)

Investments · 219 tracked

founders shown can be your intro path

By year:2026 · 6 2025 · 6 2024 · 7 2023 · 5 2022 · 2 2021 · 8 2020 · 4 2019 · 5 2018 · 6 2017 · 2 2016 · 3 2015 · 675 dated

BioAge Labsbioagelabs.com in 𝕏NASDAQ: BIOAFeb 2024 · $170M

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)in Eric Morgen(Director)inDov Goldstein(Executive Officer)in

Board Patrick Enright(Director)in

Board seatJames Healy· per SEC Form D

Co-investorsAndreessen Horowitz Elad Gil Felicis Ventures Green Sands Equity IA Seed Ventures Longitude Capital +20 more

Biomxbiomx.com in 𝕏NYSE: PHGEJan 2026SEC filingmedium confidence

BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.

AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardwareNess Ziona

Jonathan Solomon(Chief Executive Officer)inMerav Bassan(Chief Development Officer)in Marina Wolfson(Chief Financial Officer)inJesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)

Board seat Jonathan Leff· per SEC Form D · $3.3M raise · filed Jan 2026

Co-investorsAMR Action Fund Baruch Future Ventures NSG Ventures OrbiMed SBI JI Innovation Advisory Ltd.Seventure Partners +2 more

NextCurenextcure.comNASDAQ: NXTCDec 2025

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)in Udayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)in Sourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in

Board seat David Kabakoff· per SEC Form D

Co-investorsBay City Capital Canaan Partners LAV Lilly Asia Ventures Pfizer Venture Investments Quan Capital +5 more

Seaport Therapeuticsseaporttx.com in 𝕏NASDAQ: SPTXSeries A · Oct 2024 · $100M

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO & Board Member)in Steven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)in Lana Gladstein(Executive Officer)in Antony Loebel(Executive Officer)in

Board seatJames I. Healy· per SEC Form D

Co-investorsARCH Venture Partners Foresite Capital HAWKTAIL PureTech Health CPP Investments General Atlantic +3 more

Veratxveratx.com in 𝕏NASDAQ: VERAFeb 2021

Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.

BiotechDigital HealthMedical DevicesSouth San Francisco, US

Marshall Fordyce(Executive Officer, Director)in

Board Beth Seidenberg(Director)in Kurt von Emster(Director)in Patrick Enright(Director)inAndrew Cheng(Director)

Board seat Maha Katabi· per SEC Form D

Co-investorsKleiner Perkins Longitude Capital Abingworth Sofinnova Venture Partners

Aclaris Therapeuticsaclaristx.comNASDAQ: ACRS

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)in Hugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)

Co-investorsAisling Capital APERTURE Venture Partners F-Prime Capital Foresite Capital RA Capital Sofinnova Venture Partners +1 more

Anavex Life Sciencesanavex.com in 𝕏NASDAQ: AVXL

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome.

BiotechHealthtechPortola Valley, US

Alexandre Vamvakides(Executive Officer)Axel Paeger(Board Member (founder))Harvey Lalach(Executive Officer, Director)inGeorge Tidmarsh(Executive Officer, Director)Terrie Kellmeyer(Interim Chief Executive Officer)in Christopher U. Missling(Executive)in

aTYR PHARMAatyrpharma.com in 𝕏NASDAQ: ATYR

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)

Board Amir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Co-investorsCardinal Partners EcoR1 Capital Viking Global Domain Associates Domain Partners Polaris Partners +2 more

Bolt Biotherapeuticsboltbio.com in 𝕏NASDAQ: BOLT

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

Dr. Edgar G. Engleman(Founder)

Co-investorsPfizer Venture Investments Pivotal Life Sciences RA Capital Samsara BioCapital Vivo Capital Nan Fung Life Sciences +3 more

Coherus Biosciencescoherus.com in 𝕏NASDAQ: CHRS

Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.

BiotechHealthtechMedical DevicesRedwood City, US

Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)inJean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)

Co-investorsF-Prime Capital HEALTHCARE ROYALTY PARTNERS Venrock

Editas Medicineeditasmedicine.com in 𝕏NASDAQ: EDITAug 2015

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

Feng Zhang(Scientific Founder, Core Member, Broad Institute of MIT and Harvard)in George Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)in David Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in

Co-investorsEcoR1 Capital GV (Google Ventures)Viking Global Atlas Venture Deerfield Management Company Flagship Ventures +1 more

Enanta Pharmaceuticalsenanta.com in 𝕏NASDAQ: ENTA

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need.

Biotech

Jay R. Luly(President, Director and Chief Executive Officer)Yat Sun Or(Chief Scientific Officer)Scott T. Rottinghaus(Chief Medical Officer)inMatthew P. Kowalsky(Chief Legal Officer and Corporate Secretary)Tara L. Kieffer(Chief Product Strategy Officer)in Brendan Luu(Chief Business Officer)in

Co-investorsSaints Capital AbbVie

Kiniksakiniksa.com in 𝕏NASDAQ: KNSA

Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions.

BiotechMedical DevicesHamilton

THOMAS W BEETHAM(Executive Officer)inSanj K. Patel(Chief Executive Officer and Chairman of the Board)

BoardSTEPHEN R BIGGAR(Director)FELIX J BAKER(Director)G. BRADLY COLE(Director)RICHARD S LEVY(Director)

Co-investorsDeerfield Management Company Sofinnova Venture Partners

Ligandligand.com in 𝕏NASDAQ: LGNDJan 2016

Ligand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies.

BiotechFintechLa Jolla, US

Brook Byers(Co-founder)inMATTHEW W. FOEHR(Director)JOHN L. HIGGINS(Executive Officer, Director)inMATTHEW KORENBERG(Director)inCHARLES S. BERKMAN(Director)inTodd Davis(Chief Executive Officer)in

Co-investorsSignet Healthcare Partners Venrock

Mirna Therapeuticsblogmedicina.com 𝕏OTC: SYBX

A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.

BiotechMedia & EntertainmentAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)in Paul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Co-investorsNew Enterprise Associates (NEA)Pfizer Venture Investments Correlation Ventures OrbiMed Osage University Partners OUP (Osage University Partners)+1 more

Nateranatera.com in 𝕏NASDAQ: NTRA

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsBain Capital Life Sciences Cheyenne Ventures Claremont Creek Ventures Foresite Capital Harmony Partners HBM Healthcare Investments +4 more

Nucananucana.comNASDAQ: NCNA

Hugh Griffith(Founder)in

Co-investorsSofinnova Partners Scottish Enterprise

Protalixprotalix.com inNYSE: PLX

Protalix is a biopharmaceutical company that develops and manufactures innovative pharmaceutical products, including treatments for orphan and rare diseases.

BiotechHealthtechMedical DevicesKarmiel, IL

Moshe Bashan(President and Chief Executive Officer)Dror Bashan(President and Chief Executive Officer, Director)in

Co-investorsPontifax Venture Capital

Prothenaprothena.com in 𝕏NASDAQ: PRTAMar 2018

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.

BiotechDun Laoghaire, Co. Dublin, US

Tran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)Karin L. Walker(Executive Officer)inTara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)Carol D. Karp(Executive Officer)in

Co-investorsInvesco RA Capital Wellington Management

Rapport Therapeuticsrapportrx.com inNASDAQ: RAPPSeries B · Aug 2023 · $150M

Rapport is a biopharmaceutical company developing novel therapeutics.

BiotechHealthtechMedical Devices

Abe Ceesay(President)Cheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)

Co-investorsARCH Venture Partners Capital Group Johnson & Johnson Innovation – JJDC Third Rock Ventures

Seres Therapeuticsserestherapeutics.com in 𝕏NASDAQ: MCRB

Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Matthew Henn(President and Chief Scientific Officer)inJohn Aunins(Executive Officer)inEric D. Shaff(Executive Officer)in David Cook(Executive Officer)in Roger J. Pomerantz(Executive Officer, Director)inRichard N. Kender(Executive Chair and Interim Chief Executive Officer)

Co-investorsFlagship Pioneering RA Capital Fidelity Investments

Syndax Pharmaceuticals inNASDAQ: SNDX

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)in Arlene Morris(Executive Officer, Director)in Michael A. Metzger(Chief Executive Officer)in Keith A. Goldan(Chief Financial Officer)in

Board Dennis Podlesak(Director)inIvor Royston(Director)

Co-investorsForesite Capital Pappas Capital venBio Partners BlackRock Domain Associates MPM BioImpact

Synlogicsynlogictx.com in 𝕏OTC: SYBX

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)inMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)in Paul Miller(Executive Officer)inAoife Brennan(Executive Officer)inTodd Shegog(Executive Officer)in

Co-investorsAtlas Venture CLI Ventures New Enterprise Associates (NEA)NSG Ventures Pfizer Venture Investments Solasta Ventures +1 more

Alediaaledia.com inOct 2020✓ verified

Aledia develops next-generation MicroLED display technology based on 3D nanowires grown on silicon, operating a pilot line and high-volume production facility.

Deep TechHardwareSemiconductorsGrenoble, FR

philippe GILET(Founder)in

Co-investorsBraemar Energy Ventures Intel Capital Demeter Ingka Investments Supernova TEL Venture Capital, Inc.+3 more

Assia Incassia-inc.com in 𝕏✓ verified

ASSIA develops core technology for broadband internet access and network optimization, serving telecommunications service providers and network operators.

AI & Machine LearningCloud ComputingData & InfrastructureDeep TechEnterprise SoftwareRedwood City, US

John M. Cioffi(CEO and Chairman of the Board)inAssia Cioffi(Executive Vice President and Co-founder)in

Co-investorsDTCP Sofinnova Partners Stanford University Swisscom Ventures Partners for Growth Partners for Growth (PFG)

Axonis Therapeuticsaxonis.us inSeries A · Oct 2024 · $120M✓ verified

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)in Jeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in

Board Corey . Goodman(Director)in Jonathan Leff(Director)in

Co-investorsvenBio Partners MRL Ventures Fund Civilization Ventures Management, Llc Creative Destruction Lab (CDL)Hatteras Venture Partners Iaso Ventures +8 more

Expeditiontxexpeditiontx.com✓ verified

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.

BiotechHealthtechMedical DevicesSan Francisco, US

Yi Larson(Founder and CEO)Geoff Gilmartin(Chief Medical Officer)Eric Hu(Chief Business Officer)

Co-investorsForbion Novo Holdings Sanofi Ventures

Adaptive Phage Therapeuticsaphage.com in 𝕏Jun 2023SEC filingmedium confidence

Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.

AI & Machine LearningBiotechDefense TechGovTechGaithersburg, IL

Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)in

BoardEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)

Board seat Jonathan Leff· per SEC Form D · $30M raise · filed Jun 2023

Co-investorsHackensack Meridian Health Bear's Den Maryland TEDCO TEDCO AMR Action Fund Deerfield Management Company

Aeovian Pharmaceuticalsaeovian.comDec 2025

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.

BiotechBerkeley, US

Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)in Davis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)

Board seat Lars Ekman· per SEC Form D

Co-investorsCoastCap CTI Life Sciences Fund L.P.FJ Labs Luma Group venBio Partners Apollo Health Ventures +1 more

Antiva Biosciencesantivabio.com inNov 2021 · $53M

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)in Gail Maderis(Director)in Kristine Ball(President & CEO)in Elaine Chien(Executive Officer)inSarah Walter(Executive Officer)in Raju Gadiraju(Executive Officer)in

Board seat David Kabakoff· per SEC Form D

Co-investorsAdjuvant Capital Avestria Ventures Brace Pharma Canaan Partners GV (Google Ventures)HBM Healthcare Investments +6 more

Apellis Pharmaceuticalsapellis.com in 𝕏Aug 2017acquired by Biogen · May 2026 · $5.6B

NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.

BiotechCrestwood, US

Gerald Chan(Director)Stephanie O'Brien(Director)Alec Machiels(Director)Pascal Deschatelets(Executive Officer)Cedric Francois(Executive Officer, Director)

BoardA. Sinclair Dunlop(Director)

Board seat Maha Katabi· per SEC Form D

Co-investorsAvoro Capital Advisors EMBL Ventures Epidarex Capital F-Prime Capital Keyhorse Capital Solasta Ventures +1 more

Arriventarrivent.com inSeries B · Dec 2022 · $160M

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)in Brent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Board seatJames Healy· per SEC Form D

Co-investorsCatalio Capital Management, LP Foresite Capital General Catalyst HBM Healthcare Investments HBM Partners HongShan Capital Group +4 more

ARS Pharmaceuticalsars-pharma.com in 𝕏Sep 2021SEC filingmedium confidence

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

Board seat Jonathan Leff· per SEC Form D · $55M raise · filed Sep 2021

Co-investorsNextech Invest OrbiMed RA Capital SR One Capital Management

Dracen Pharmaceuticalsdracenpharma.comAug 2023SEC filingmedium confidence

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.

BiotechHealthtechBaltimore, US

Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)

BoardRobert Jackson(Director)

Board seat Jonathan Leff· per SEC Form D · $2.8M raise · filed Aug 2023

Co-investorsBiotech Investments S.R.O i&i Biotech Fund OUP (Osage University Partners)Deerfield Management Company

Effector Therapeuticseffector.comDec 2015SEC filingmedium confidence

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in

BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Board seat Maha Katabi· per SEC Form D · $56M raise · filed Feb 2016

Co-investorsAstellas Venture Management LLC Mission Bay Capital Mission Biocapital OUP (Osage University Partners)Pfizer Venture Investments US Venture Partners

Genoa Pharmaceuticalsgenoa-pharmaceuticals.appspot.comOct 2023SEC filingmedium confidence

Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.

BiotechHealthtechSan Diego, US

Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)

BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)

Board seat Jonathan Leff· per SEC Form D · $189.2M raise · filed Oct 2023

Co-investorsF-Prime Capital Norwest Venture Partners RiverVest Venture Partners

Quanta Therapeuticsquantatx.comJun 2026 · $50M

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.

BiotechDeep TechHealthtechSouth San Francisco, US

Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)

Board Perry Nisen(Executive Officer, Director)in Maria Fardis(Director)in Rajul Jain(Director)in

Board seat Maha Katabi· per SEC Form D

Co-investorsFinchley Healthcare Ventures Longitude Capital Vida Ventures Biotechnology Value Fund Frazier Life Sciences

Rarecyterarecyte.comJul 2023SEC filingmedium confidence

Seattle, US

Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)in Joseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)

Board Robert Shepler(Director)in

Board seat David Kabakoff· per SEC Form D · $35.7M raise · filed Jul 2023

Co-investors5AM Ventures Arboretum Ventures F-Prime Capital Telegraph Hill Partners HealthQuest Capital

Rayze Biorayzebio.com inSep 2022 · $160M

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)

Board Aaron Royston(Director)in

Board seat Maha Katabi· per SEC Form D

Co-investorsLifeSci Venture Partners Samsara BioCapital Scion Life Sciences TCG Crossover venBio Partners Versant Ventures +3 more

Route 92 Medicalr92m.com in 𝕏Jan 2026SEC filingmedium confidence

Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.

BiotechHardwareHealthtechMedical DevicesSan Mateo, US

Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)inDr. Joey English(Chief Medical Officer)Tony Chou(Executive Officer, Director)in

Board Jack Lasersohn(Director)inTamir Meiri(Director)

Board seatNoel Jee· per SEC Form D · $50M raise · filed Apr 2026

Co-investorsNovo Holdings The Vertical Group Norwest Venture Partners Runway Growth Capital US Venture Partners Sectoral Asset Management +1 more

Star Therapeuticsstar-therapeutics.comSeries C · Oct 2025 · $90M

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in

Board seat Maha Katabi· per SEC Form D

Co-investorsFrazier Life Sciences OrbiMed RA Capital Sanofi Ventures Viking Global Agent Capital +11 more

Acceleronacceleronpharma.com in 𝕏Dec 2011

A pharmaceutical company that develops medicines and vaccines for patients globally.

BiotechHealthtechMedical DevicesCambridge, US

WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)inKEVIN F. MCLAUGHLIN(Executive Officer)inMATTHEW L. SHERMAN(Executive Officer)

Co-investorsBessemer Venture Partners Foresite Capital Lightstone Ventures Lowercarbon Capital Venrock Collaborative Fund

Aerie Pharmaceuticalsaeriepharma.com inSep 2014

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in

Co-investorsAlta Partners Avoro Capital Advisors Foresite Capital OUP (Osage University Partners)

Aerovatetxaerovatetx.comacquired by Jade Biosciences

BiotechHealthtech

Aerpio Therapeuticsaerpio.com

BiotechCincinnati, US

Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)Ian A.W. Howes(Executive Officer)

Co-investorsCincyTech Ally Bridge Group OrbiMed

Afyxtxafyxtx.com

AFYX is a biopharmaceutical company focused on reformulation and repurposing of existing pharmaceuticals for conditions including head and neck cancer, labor induction, cluster headaches, and pain and addiction.

BiotechHealthtechMedical DevicesHørsholm, DK

Dr. Claus J. Møller-San Pedro(CEO)

Aiolos Bioaiolosbio.com in 𝕏

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsBain Capital Life Sciences RA Capital

Akouosakouos.com inAug 2018 · $50M

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in

Board Ed Mathers(Director)in Kush Parmar(Director)in

Co-investors5AM Ventures EcoR1 Capital New Enterprise Associates (NEA)Pivotal Life Sciences RA Capital Cowen Healthcare Investments +2 more

Alimerasciencesalimerasciences.comacquired by ANI Pharmaceuticals

BiotechHealthtechMedical Devices

Co-investorsNew Enterprise Associates (NEA)

Alkeuspharmaalkeuspharma.com in 𝕏

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Carlos Quezada-Ruiz(Chief Medical Officer)in

Co-investorsBain Capital Life Sciences TCG Crossover Wellington Management

Alvinepharmaalvinepharma.com 𝕏

Amarinamarincorp.com in 𝕏

Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.

BiotechHealthtechMedical Devices

Co-investorsAvoro Capital Advisors Fountain Healthcare Partners Longitude Capital Signet Healthcare Partners

Amplyxamplyx.comMay 2020

Developing a new class of antifungal medicine to overcome limitations of current therapies.

Co-investorsBioBrit Golden Seeds Keiretsu Forum Pappas Capital 3x5 Partners Arix Bioscience +4 more

Anesivaanesiva.com

Anesiva is a biopharmaceutical company developing Nexletol for diet management.

Biotech

Antheraanthera.com

Anthera produces makeup and skincare products made in France with natural, non-toxic ingredients that are cruelty-free and vegan.

ConsumerWellness & FitnessFrance, FR

Co-investorsPappas Capital VantagePoint Capital Partners

Apeiron Therapeuticsapeiron-bio.com in

Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechBurlingame, US

Mingxi Li(CEO)in Fred Aswad(Chief Scientific Officer)in

Co-investorsPanacea Venture

Apollo Health Venturesapollo.vc in 𝕏Jan 2026

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

Nils Regge(Co-Founder & General Partner)in

Co-investorsBLN Capital CoastCap FJ Labs KfW Capital TruVenturo GmbH CTI Life Sciences Fund L.P.+3 more

Arcus Biosciencesarcusbio.com in 𝕏

Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.

BiotechHealthtech

Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRichard Markus(Chief Medical Officer)inCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)

Co-investorsAisling Capital Decheng Capital Droia Ventures EcoR1 Capital Foresite Capital GV (Google Ventures)+4 more

ARTBIOartbio.com in 𝕏Series B · Jul 2025 · $130M

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)Nicole Hadas(Chief Legal Officer)

Co-investorsB Capital Group B4 Capital F-Prime Capital Alexandria B Capital Omega Funds +2 more

Ascendis Pharmaascendispharma.com in 𝕏Nov 2014

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in

Co-investorsVivo Capital Aisling Capital Avoro Capital Advisors Foresite Capital RA Capital Sofinnova Partners

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Aerovate Therapeutics, Inc.Atsena Therapeutics, Inc.Bolt Therapeutics Cleveland DiagnosticsElektrofi, Inc.Gyroscope Therapeutics LtdMarea Therapeutics, Inc.Neurana PharmaceuticalsAchaogenAcrotech PharmaceuticalsActelionActimis PharmaceuticalsAdeona BiotechAdvanced Oxygen TherapeuticsAlimera SciencesAmarantus BioscienceAmplyx PharmaceuticalsAnthera PharmaAnthera PharmaceuticalsAntheriX TherapeuticsApollohealAppulse CorporationAralez PharmaceuticalsAsyndetan HoldingsAthena TherapeuticsAtsena TherapeuticsAudentes TherapeuticsAuris PharmaceuticalsAurismedicalAveXisBioDelivery SciencesCatalystbiosciencesCaveoGelCebixChameleon PharmaChimera TherapeuticsCinCorCinCor PharmaCompugen TherapeuticsCoTherixDauntlessphEar PharmaceuticalsEdgeEdge TherapeuticsEntasis TherapeuticsEntellus MedicalFirstaidshottherapyGenitopeHeartSpan TechnologiesHumanigenHumanity TherapeuticsHyperion TherapeuticsHyperiontxInnocollInozymeIntellikineIntransaIntrepidabioKalyotaKaruna TherapeuticsLifegen BiotechnologiesMedeor TherapeuticsMeru TherapeuticsMetacelMisonixNeos TherapeuticsNeuranapharmaNexigen BiopharmaNucleonyx PharmaceuticalsOrexigenPharmaSonicsPhocéa PharmaPregLemProdigy BiotechProgenics PharmaceuticalsRainierrxRaptor PharmaceuticalsReata PharmaceuticalsRetinal ImplantRXSTATUSSaegis PharmaceuticalsSangamo BiotherapeuticsSeagenSensei BiotherapeuticsSerica TechnologiesSorbent Therapeutics

Browse all 219 investments with full details →

▶19 more tracked companies

Spark Therapeutics SparktxSybios CorporationSyros PharmaceuticalsTensysmedicalTransgenomicTranslate BioTriusrxTSROVelosbioVera TherapeuticsVersartisVesalius TherapeuticsVicepttxVion PharmaceuticalsVisen PharmaceuticalsXyloCor Therapeutics Ymabs ZS Pharma

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 52

23 IPOs · 29 acquisitions · showing 44

BioAge LabsNASDAQ: BIOABiomxNYSE: PHGENextCureNASDAQ: NXTCSeaport TherapeuticsNASDAQ: SPTXVeratxNASDAQ: VERAAclaris TherapeuticsNASDAQ: ACRSAnavex Life SciencesNASDAQ: AVXLaTYR PHARMANASDAQ: ATYRBolt BiotherapeuticsNASDAQ: BOLTCoherus BiosciencesNASDAQ: CHRSEditas MedicineNASDAQ: EDITEnanta PharmaceuticalsNASDAQ: ENTAKiniksaNASDAQ: KNSALigandNASDAQ: LGNDMirna TherapeuticsOTC: SYBXNateraNASDAQ: NTRANucanaNASDAQ: NCNAProtalixNYSE: PLXProthenaNASDAQ: PRTARapport TherapeuticsNASDAQ: RAPPSeres TherapeuticsNASDAQ: MCRBSyndax PharmaceuticalsNASDAQ: SNDXSynlogicOTC: SYBXApellis Pharmaceuticalsacq. by BiogenAerovatetxacq. by Jade BiosciencesAlimera Sciencesacq. by ANI PharmaceuticalsAlimerasciencesacq. by ANI PharmaceuticalsBioDelivery Sciencesacq. by Collegium PharmaceuticalEdge Therapeuticsacq. by PDS Biotechnology Corp.Entellus Medicalacq. by StrykerForty Seven Incacq. by GileadInozymeacq. by BioMarin Pharmaceutical Inc.InterMuneacq. by RocheMisonixacq. by BioventusNeos Therapeuticsacq. by Aytu BioScience (later Aytu BioPharma)Nextwavepharmaacq. by Tris PharmaProgenics Pharmaceuticalsacq. by Lantheus HoldingsProteostasis Therapeuticsacq. by Yumanity TherapeuticsRaptor Pharmaceuticalsacq. by Horizon PharmaReata Pharmaceuticalsacq. by BiogenSaegis Pharmaceuticalsacq. by H. Lundbeck A/SSeagenacq. by PfizerSeattle Geneticsacq. by PfizerSerica Technologiesacq. by Allergan

Portfolio news

latest coverage across their companies

Ligand Reports Second Quarter 2026 Financial Results | Markets Insider

Ligand · markets.businessinsider.com · Aug 6, 2026

City Therapeutics Raises $99.5M in Series B Funding

City Therapeutics · finsmes.com · Jun 9, 2026

Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline

Coultreon · coultreon.com · Apr 28, 2026

Global Healthcare and Life Sciences Venture Funding – 2025 Review - DealForma

DealForma · dealforma.com · Feb 6, 2026

Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment

Athira · geekwire.com · Dec 18, 2025

Aeovian Pharmaceuticals Raises $55M in Funding

Aeovian Pharmaceuticals · finsmes.com · Dec 16, 2025

Star Therapeutics Announces Oversubscribed $125 Million Series D Financing – STAR Therapeutics

Star Therapeutics · star-therapeutics.com · Sep 30, 2025

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure

ARTBIO · prnewswire.com · Jul 29, 2025

Fund performance · per public LP disclosures · 4

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Sofinnova Venture Partners IXLPs: California State Teachers' Retirement System	2014	—	7.2%	1.47x	1.01x
SOFINNOVA VENTURE PARTNERS VIII LPLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System, University of Texas Investment Management Company	2011	—	21.9%	1.66x	1.66x
Sofinnova Venture Partners VIILPs: Oregon Public Employees Retirement System	2007	—	14.7%	1.71x	1.71x
Sofinnova Venture Partners VILPs: Orange County Employees Retirement System	1999	—	-19.8%	0.10x	0.15x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings · 3

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Seaport Therapeutics	5.2%	$18.00	May 2026	$49.2M
BioAge Labs	4.8%	$18.00	Sep 2024	$29.5M
Rapport Therapeutics	3.9%	$17.00	Jun 2024	$23.7M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Public market activity · per SEC filings

what is this? ⓘ

ArriVent BioPharma, Inc.SC 13G

Disclosed stake · filed Nov 2024

view filing ↗

BioAge Labs, Inc.SC 13D

Disclosed stake · filed Sep 2024

view filing ↗

Rapport Therapeutics, Inc.SC 13D

Disclosed stake · filed Jun 2024

view filing ↗

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Sofinnova Ventures made?: Sofinnova Ventures has 219 tracked investments, 52 of which have exited, including 15 dated in the last 24 months.
What stage does Sofinnova Ventures invest at?: Sofinnova Ventures invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Sofinnova Ventures's typical check size?: Sofinnova Ventures typically writes checks of $100K – $15M.
What sectors does Sofinnova Ventures focus on?: Sofinnova Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Sofinnova Ventures located?: Sofinnova Ventures is headquartered in Menlo Park, US.
Does Sofinnova Ventures lead rounds?: Sofinnova Ventures typically participates in rounds rather than leading them.
Who does Sofinnova Ventures co-invest with?: Sofinnova Ventures most often shares deals with RA Capital, Foresite Capital, New Enterprise Associates (NEA), among 150 tracked co-investors.

Images

Co-investors · 30

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 16

Mirna Therapeutics Synlogic Akouos Amplyx Amplyx Pharmaceuticals Athira Avenzo Galera Therapeutics Hyperion Therapeutics Inozyme Pharma ObsEva Orexigen Therapeutics Pionyr Immunotherapeutics Proteostasis TherapeuticsAlimerasciencesCatalystbiosciences

$200K – $40M

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 15

BioAge Labs Biomx Mirna Therapeutics NextCure Synlogic Aerpio Therapeutics Arrivent ARS Pharmaceuticals Avenzo Civitas Therapeutics Oncusp Therapeutics Pionyr Immunotherapeutics Principia Biopharma Star Therapeutics Velosbio

$1M – $75M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 10

Aclaris Therapeutics Coherus Biosciences Apellis Pharmaceuticals ARTBIO Checkmate Pharmaceuticals Genoa Pharmaceuticals Nextwavepharma Oncusp Therapeutics Proteostasis Therapeutics Rarecyte

$3M – $10M

venBio Partners

venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.

Both backed · 10

Seaport Therapeutics Syndax Pharmaceuticals Aeovian Pharmaceuticals Apellis Pharmaceuticals Axonis Therapeutics Checkmate Pharmaceuticals Marea Therapeutics, Inc.Northsea Therapeutics Rayze BioMarea

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 8

Rapport Therapeutics Seaport Therapeutics Chiasma City Therapeutics Karunatx Mallinckrodt Sorbent Therapeutics Vesalius Therapeutics

$50K – $250M

Third Rock Ventures

Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.

Both backed · 8

BioAge Labs Rapport Therapeutics Seaport Therapeutics ARTBIO Jounce Therapeutics Marea Therapeutics, Inc.Neon TherapeuticsKaruna Therapeutics

$100K – $5M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 7

NucanaAscendis Pharma Assia Inc CinCor Pharma ObsEva VelosbioPregLem

$540K – $27M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 6

Editas Medicine Antiva Biosciences Arcus Biosciences Forty Seven Inc Gritstone bioVera Therapeutics

$250K – $50M

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

Both backed · 6

NextCure Antiva Biosciences Civitas Therapeutics Iterum Iterum Therapeutics Marinus Pharmaceuticals

$500K – $20M

Forbion

Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.

Both backed · 6

Capstan Therapeutics Coultreon Expeditiontx Northsea Therapeutics PromediorGyroscope Therapeutics Ltd

Pivotal Life Sciences

Pivotal Life Sciences is a global healthcare investment firm backing companies developing high-impact therapeutics for major unmet medical needs, operating across venture capital, venture building, and public equity strategies.

Both backed · 6

BioAge Labs Bolt Biotherapeutics Akouos Inozyme Pharma KarunatxInozyme

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.

Both backed · 4

Veratx Star TherapeuticsTSROVera Therapeutics

$500K – $15M

▶18 more co-investors

SR One Capital Management Sanofi Ventures Abingworth Vida Ventures Westlake Village BioPartners Andreessen Horowitz Sequoia Capital General Catalyst B Capital Group Entrepreneur First Johnson & Johnson Innovation – JJDC Cambridge Innovation Capital Morgenthaler Novartis Venture Fund Frazier Healthcare Partners VantagePoint Capital Partners BoxOne Ventures ACORN BIOVENTURES

Firms observed investing alongside Sofinnova Ventures, from public investor directories. Shared companies are the overlap with Sofinnova Ventures's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Seed Investors & VC Firms in North America Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Investors & VC Firms in Global Series B Investors & VC Firms Series A Investors & VC Firms in United States Healthtech Investors & VC Firms

Website & social

sofinnova.com

/sofinnova-ventures @SofinnovaUS watch video

signal ↗crunchbase ↗

As published on the firm's website.

Contact

Menlo Park3000 Sand Hill Rd
Building 3-Suite 150
Menlo Park, CA 94025
United States

BostonOne Marina Park Drive
Suite 300
Boston, MA 02210
United States

New York27 West 24th Street
Suite 302
New York, NY 10010
United States

Emailinfo@sofinnova.com

Phone(650) 681-8420

Fax(650) 322-2037

FoxScore

Combines investment activity, responsiveness, founder feedback, closing rate and follow-through reported by founders on Fox. Sign up to see it.

Your history

Sofinnova Ventures isn't in your CRM yet.

+ Add to CRM

Track outreach, deck opens, and next steps across your whole raise.

✨ Smart outreach

✨ Best warm path

Funds

SOFINNOVA VENTURE PARTNERS XII, L.P.vintage 2024 · 75 LPs · 506(c)$20.5MAUM

SOFINNOVA VENTURE PARTNERS XI, L.P.vintage 2021 · 52 LPs · 506(b)$308.7MAUM

SOFINNOVA BIOEQUITIES ENHANCED MASTER FUND, LPMar 2026 · 28 LPs$1.2BAUM

SOFINNOVA VENTURE PARTNERS X, L.P.Mar 2026 · 60 LPs$259.3MAUM

SOFINNOVA BIOEQUITIES MASTER FUND, LTD.Mar 2026 · 50 LPs$121.4MAUM

SOFINNOVA SYNERGY MASTER FUND, LPMar 2026

+1 more funds

Source: SEC Form ADV Schedule D and EDGAR Form D filings. AUM is gross asset value as reported by the adviser.

Latest on 𝕏

Sofinnova Investments @sofinnovaus

This year, Sofinnova celebrates 50 years of partnering with visionary entrepreneurs to advance breakthrough science and help bring innovative therapies to patients. We're proud of what we've accomplished together, and we're even more excited about what's ahead as scientific https://t.co/iikelHx7Qd

Jul 30, 2026 · ♥ 1 · ⇄ 1

Sofinnova Investments @sofinnovaus

Congratulations to the Claris Biotherapeutics team on today’s launch and successful $118 million Series B financing. We at @SofinnovaUS are excited to support Claris alongside an outstanding investor syndicate to advance CSB-001 (oremepermin alfa ophthalmic solution) in limbal https://t.co/93RH2zOV4S

Jul 28, 2026

Sofinnova Investments @sofinnovaus

@SofinnovaUS Executive Partner @MahaRadhakrish2 speaks with @biospace on AI Data Becomes Sticking Point in Biopharma Dealmaking https://t.co/wfbGyIglce https://t.co/NVk3oeRbo6

Jul 24, 2026